Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
25 Ottobre 2023 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that it will report its third-quarter 2023 financial
results on Wednesday, November 8, 2023. Vericel’s management will
host a conference call and webcast at 8:30 a.m. (ET) to discuss its
financial results and business highlights.
The live webcast can be accessed on the Investor Relations
section of the Vericel website at
http://investors.vcel.com/events-presentations. Please visit the
site at least 15 minutes prior to the scheduled start time in order
to register and download the required audio software, if necessary.
Presentation slides for the conference call will be available on
the webcast and on the Investor Relations section of the Vericel
website.
To participate by telephone, please register here to receive
dial-in details and your personal passcode. A replay of the webcast
will be available on the Vericel website until November 8,
2024.
About Vericel Corporation
Vericel is a leader in advanced therapies for sports medicine
and severe burn care. The Company manufactures and markets two cell
therapy products and one specialty biologic product in the United
States. MACI® (autologous cultured chondrocytes on porcine collagen
membrane) is an autologous cellularized scaffold product indicated
for the repair of symptomatic, single or multiple full-thickness
cartilage defects of the knee with or without bone involvement in
adults. Epicel® (cultured epidermal autografts) is a permanent skin
replacement for the treatment of patients with deep dermal or full
thickness burns greater than or equal to 30% of total body surface
area. Vericel also holds an exclusive license for North American
rights to NexoBrid® (anacaulase-bcdb), a biological orphan product
containing proteolytic enzymes, which is indicated for the removal
of eschar in adults with deep partial-thickness and/or
full-thickness burns. For more information, please visit
www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2023 Vericel
Corporation. All rights reserved.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
Media Contact:
Julie Downs
media@vcel.com
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Vericel (NASDAQ:VCEL)
Storico
Da Mag 2023 a Mag 2024